Yttrium-90-loaded microsphere (Y-90 microsphere)

The phrase "Tumor cell irradiation via beta emission from yttrium‑90-loaded microsphere deposition in hepatic vasculature" does not refer to a molecular target such as a receptor, enzyme, or transporter. Instead, it describes a therapeutic procedure known as yttrium‑90 radioembolization or selective internal radiation therapy (SIRT). In this treatment, tiny glass or resin beads loaded with the radioactive isotope yttrium‑90 are delivered through the hepatic artery directly into liver tumors. The microspheres become lodged in the tumor’s blood supply and emit localized beta radiation that destroys tumor cells while sparing most healthy tissue. This approach is used primarily for unresectable liver cancers—including hepatocellular carcinoma and metastatic tumors—where it can shrink tumors and improve patient outcomes. It is not itself a druggable molecular target but rather an interventional radiology technique using physical agents to deliver targeted radiotherapy. Because this entry refers to a therapeutic method rather than a specific molecule/receptor/target protein, it should be flagged as incorrect for structured target databases. Key points: Yttrium‑90-loaded microspheres are not biological targets but delivery vehicles for local radiotherapy; thus, they do not fit standard molecular classification schemes used for receptors or enzymes.

Other names

Yttrium-90 radioembolizationSelective internal radiation therapy (SIRT)RadioembolizationTheraSphere (glass-based)SIR-Spheres (resin-based)